CClinicalTrials.gg
Active, not recruitingNCT07329998Updated Jan 9, 2026

The Aim of the Study is to Check Whether Follicular Fluid Evaluation Using a Spectrophotometer Can Differentiate High Quality Oocytes From Low Quality Oocytes. Oocyte Quality Will be Defined Using GDF9, BMP15 and Oocyte Morphology.

An interventional study of Oocyte quality assessment using spectrophotometer in Oocyte Quality Assessment Using Spectrophotometer, sponsored by Hillel Yaffe Medical Center. Active, not recruiting at 1 site in Israel. Open to female participants. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Hillel Yaffe Medical Center · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2024, registered Nov 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Sex
Female
01

Study summary

The aim of the study is to check whether follicular fluid evaluation using a spectrophotometer can differentiate high quality oocytes from low quality oocytes. Oocyte quality will be defined using GDF9, BMP15 and oocyte morphology. The correlation between cortisol levels in women and oocyte quality parameters will be estimated.

02

Conditions studied

  • Oocyte Quality Assessment Using Spectrophotometer
03

In context

Lead sponsor

Hillel Yaffe Medical Center is the lead sponsor of 301 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women aged 20-40 years.
  • Undergoing IVF or IVF-ICSI treatment.
  • At least five follicles visualized on ultrasound at the time of oocyte retrieval
  • Ability to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Age >40 years.
  • Fewer than five follicles at the time of oocyte retrieval.
  • Use of donor oocytes.
  • Significant medical comorbidities affecting ovarian function.
  • Known ovarian malignancy or prior ovarian surgery significantly affecting follicular integrity.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    follicular fluid evaluation using spectrophotometer to differentiate high low quality oocytes

    Procedure: Oocyte quality assessment using spectrophotometer

Interventions

  • ProcedureOocyte quality assessment using spectrophotometer

    On the OPU (ovum pick-up) day the following blood biochemical markers will be measured as well- Blood interleukins 1-6, cytokine, hormone profile, lipid profile, cortisol. After collecting the oocytes- the Follicular fluid will be sent for the following tests- 1. mid-infrared spectrometry, 2. P, E2, testosterone, cortisol, cytokines, IL 1-6, lipids, fatty acids. 3. BMP-15, GDF-9 and HSPG2 4. GCMS-Gas Chromatography Mass Spectrophotometer

06

What researchers measure

Primary outcomes

  1. Difference in follicular fluid infrared spectrophotometric profiles between high-quality and low-quality oocytes.

    Infrared spectrophotometric measurements of follicular fluid collected at oocyte retrieval will be obtained using attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FTIR). Oocytes will be classified as high-quality or low-quality based on predefined morphological criteria and follicular fluid levels of GDF9 and BMP15 measured by ELISA. The primary outcome will be reported as differences in normalized spectral absorbance features between the two oocyte quality groups, including discrimination performance using multivariate analysis.

    Time frame: 3 Years

07

Study locations

1 site
  • Hille Yaffe Medical Center
    Hadera, Israel 3881000, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07329998
Lead sponsor
Hillel Yaffe Medical Center
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Sep 22, 2024
Primary completion
Dec 16, 2025
Completion
Nov 1, 2026 (estimated)
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion